Hematoma formation is more frequent with
**Core Concept**
Hematoma formation in the context of anticoagulant therapy or surgical procedures is influenced by the balance between blood clotting and bleeding. Anticoagulants work by inhibiting the coagulation cascade, thereby increasing the risk of bleeding and hematoma formation. The choice of anticoagulant and the underlying patient factors determine the risk of hematoma.
**Why the Correct Answer is Right**
The correct answer is related to the class of anticoagulants that have a higher risk of bleeding complications, including hematoma formation. This is because they inhibit the synthesis of vitamin K-dependent clotting factors, which are essential for blood coagulation. The most notable class of anticoagulants that increase the risk of hematoma is the **vitamin K antagonists (VKAs)**, such as warfarin. VKAs inhibit the production of vitamin K-dependent clotting factors (II, VII, IX, and X), leading to a prolonged prothrombin time and an increased risk of bleeding.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as it does not specify a particular class of anticoagulants that increase the risk of hematoma. While all anticoagulants carry a risk of bleeding, the question asks for the class of anticoagulants that are more frequent with hematoma formation.
**Option B:** This option is incorrect as it is a class of anticoagulants that actually reduce the risk of bleeding complications. Antiplatelet agents, such as aspirin, work by inhibiting platelet aggregation, thereby reducing the risk of thrombosis but increasing the risk of bleeding.
**Clinical Pearl / High-Yield Fact**
When managing patients on anticoagulant therapy, it is essential to weigh the risks and benefits of different anticoagulants and adjust the treatment regimen accordingly. Patients on VKAs require regular monitoring of INR levels to ensure that they are within the therapeutic range, as excessive anticoagulation increases the risk of bleeding complications.
**Correct Answer:** D. VKAs (Vitamin K Antagonists)